Cantel Medical (CMD) is a high quality growth company that is likely to significantly grow its earnings over the next 5 years. The company supplies a diverse set of very stable and growing medical end-markets. The company has a strong track record of generating organic growth but has also demonstrated an ability to grow inorganically through bolt-on acquisitions.
Cantel’s stock price has recently fallen 23% from $130 to $100 after the company missed earnings estimates and guided investors to expect revenue growth of 12.75% revenue growth instead of the 13.5% revenue growth it